1. COVID-19 medical papers have fewer women first authors than expected.
- Author
-
Andersen JP, Nielsen MW, Simone NL, Lewiss RE, and Jagsi R
- Subjects
- COVID-19, Efficiency, Female, Humans, Medicine, Periodicals as Topic statistics & numerical data, Physicians, Women statistics & numerical data, Sex Factors, Social Isolation, United States, Authorship, Bibliometrics, Coronavirus Infections, Pandemics, Pneumonia, Viral, Research Personnel statistics & numerical data, Women
- Abstract
The COVID-19 pandemic has resulted in school closures and distancing requirements that have disrupted both work and family life for many. Concerns exist that these disruptions caused by the pandemic may not have influenced men and women researchers equally. Many medical journals have published papers on the pandemic, which were generated by researchers facing the challenges of these disruptions. Here we report the results of an analysis that compared the gender distribution of authors on 1893 medical papers related to the pandemic with that on papers published in the same journals in 2019, for papers with first authors and last authors from the United States. Using mixed-effects regression models, we estimated that the proportion of COVID-19 papers with a woman first author was 19% lower than that for papers published in the same journals in 2019, while our comparisons for last authors and overall proportion of women authors per paper were inconclusive. A closer examination suggested that women's representation as first authors of COVID-19 research was particularly low for papers published in March and April 2020. Our findings are consistent with the idea that the research productivity of women, especially early-career women, has been affected more than the research productivity of men., Competing Interests: JA, MN, NS No competing interests declared, RL Founder of TIME'S UP Healthcare, a non-profit initiative that advocates for safety and equity in healthcare; advisor for FeminEM.org, a website that supports the careers of women in medicine. RJ Has stock options as compensation for her advisory board role in Equity Quotient, a company that evaluates culture in health care companies; has received personal fees from Amgen and Vizient and grants for unrelated work from the National Institutes of Health, the Doris Duke Foundation, the Greenwall Foundation, the Komen Foundation, and Blue Cross Blue Shield of Michigan for the Michigan Radiation Oncology Quality Consortium; has a contract to conduct an investigator-initiated study with Genentech; has served as an expert witness for Sherinian and Hasso and Dressman Benzinger LaVelle; uncompensated founding member of TIME'S UP Healthcare; member of the Board of Directors of ASCO., (© 2020, Andersen et al.)
- Published
- 2020
- Full Text
- View/download PDF